RockfishBio AG
Rockfish Bio AG develops senolytic therapies to promote healthy aging and treat age-related diseases.
About
Rockfish Bio AG is an Austria-based biotechnology company focused on developing novel senolytic drug candidates that specifically target and remove senescent cells, which are dysfunctional cells implicated in aging and a variety of chronic diseases. By leveraging metabolic pathways unique to senescent cells, Rockfish Bio's compounds aim to eliminate these cells without affecting healthy tissues, thus promoting healthy aging and addressing diseases such as chronic kidney disease, diabetes, cardiovascular diseases, liver fibrosis, neurodegenerative diseases, sarcopenia, immunosenescence, lung diseases, osteoarthritis, and frailty. The company's mission is to extend both lifespan and healthspan through innovative therapeutics.
Products & Services
- IAAC-based senolytic therapies
- mRNA-based senolytic therapeutics
- Lead compound RFB01016 for healthspan and lifespan extension, reducing senescent cells and improving neuromuscular function
- Drug development for age-related diseases
Use Cases & Case Studies
- Preclinical studies demonstrating lifespan and healthspan extension and restoration of neuromuscular function in animal models
Partnerships & Collaborations
- Spin-off from University of Natural Resources and Life Sciences Vienna (BOKU) and Medical University of Vienna
- Supported by Austria Wirtschaftsservice Gesellschaft mbH (AWS) PreSeed funding program
Awards & Recognition
- Science and Business Award 2025